Craig-Hallum Maintains Buy on Cellebrite DI, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Jeff Van Rhee maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $16 to $20.
August 16, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Craig-Hallum analyst Jeff Van Rhee maintains a Buy rating on Cellebrite DI and raises the price target from $16 to $20.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively influence investor sentiment and drive short-term price appreciation for CLBT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100